# Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia

> **NCT01231841** · PHASE2 · COMPLETED · sponsor: **The Cleveland Clinic** · enrollment: 20 (actual)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** cyclosporine
- **BIOLOGICAL:** anti-thymocyte globulin

## Key facts

- **NCT ID:** NCT01231841
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01231841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01231841, "Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01231841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*